Wells Fargo
TARS icon

Wells Fargo’s Tarsus Pharmaceuticals TARS Stock Holding History

Wells Fargo’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.03M Buy
111,639
+22,346
+25% +$1.43M ﹤0.01% 2516
2026
Q1 		$6.26M Sell
89,293
-29,765
-25% -$2.08M ﹤0.01% 2417
2025
Q4 		$9.75M Buy
119,058
+20,307
+21% +$1.52M ﹤0.01% 2068
2025
Q3 		$5.87M Sell
98,751
-28,202
-22% -$1.39M ﹤0.01% 2437
2025
Q2 		$5.14M Buy
126,953
+67,110
+112% +$3.02M ﹤0.01% 2448
2025
Q1 		$3.07M Buy
59,843
+2,839
+5% +$140K ﹤0.01% 2801
2024
Q4 		$3.16M Buy
57,004
+17,451
+44% +$793K ﹤0.01% 2814
2024
Q3 		$1.3M Buy
39,553
+26,070
+193% +$733K ﹤0.01% 3368
2024
Q2 		$366K Buy
13,483
+1,609
+14% +$54.1K ﹤0.01% 4115
2024
Q1 		$432K Buy
11,874
+2,011
+20% +$59.1K ﹤0.01% 3987
2023
Q4 		$200K Buy
9,863
+2,539
+35% +$42.4K ﹤0.01% 4467
2023
Q3 		$130K Sell
7,324
-2,365
-24% -$41.9K ﹤0.01% 4618
2023
Q2 		$175K Buy
9,689
+5,679
+142% +$90.3K ﹤0.01% 4668
2023
Q1 		$50.4K Buy
4,010
+1,067
+36% +$15.6K ﹤0.01% 5155
2022
Q4 		$43.1K Sell
2,943
-163
-5% -$2.7K ﹤0.01% 4929
2022
Q3 		$53K Buy
3,106
+61
+2% +$969 ﹤0.01% 4929
2022
Q2 		$45K Sell
3,045
-1,668
-35% -$25K ﹤0.01% 5077
2022
Q1 		$79K Sell
4,713
-2,941
-38% -$54.6K ﹤0.01% 5435
2021
Q4 		$172K Sell
7,654
-2,130
-22% -$55.4K ﹤0.01% 5350
2021
Q3 		$210K Buy
+9,784
New +$242K ﹤0.01% 5074
2021
Q2 		– Sell
-1,941
Closed -$63K – 7421
2021
Q1 		$63K Sell
1,941
-1,252
-39% -$46.3K ﹤0.01% 5703
2020
Q4 		$132K Buy
+3,193
New +$91K ﹤0.01% 5248

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Wells Fargo's TARS Position: Q2 2026 in Review

Wells Fargo increased its Tarsus Pharmaceuticals (TARS) stake by 25% in Q2 2026, buying an estimated $1.43M and bringing the position to 111,639 shares worth $7.03M. The position accounts for ﹤0.01% of the portfolio, ranked #2516.

Wells Fargo first reported a position in TARS in Q4 2020 and has held it in 22 quarters since. The position peaked at $9.75M in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Wells Fargo held 111,639 shares of Tarsus Pharmaceuticals worth $7.03M as of Q2 2026.
  • Wells Fargo bought 22,346 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $1.43M.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #2516 holding.
  • Wells Fargo first reported a position in Tarsus Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • Wells Fargo's Tarsus Pharmaceuticals position peaked at $9.75M in Q4 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.